section name header

Pronunciation

EL-a-GOE-lix

Classifications

Therapeutic Classification: analgesics

Pharmacologic Classification: gnrh antagonist

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Rapidly absorbed.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A isoenzyme with some metabolism by the CYP2D6 and CYP2C8 isoenzymes as well as UGT. 90% of dose excreted in feces, <3% in urine.

Half-life: 4–6 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash.

Endo: hot flush, night sweats.

GI: nausea, liver enzymes, abdominal pain, constipation, diarrhea.

GU: libido, menstrual irregularities.

Metab: weight, dyslipidemia.

MS: bone density, arthralgia.

Neuro: headache, anxiety, depression, dizziness, insomnia, mood swings, SUICIDAL THOUGHTS/BEHAVIOR.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Route/Dosage

Hepatic Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Orilissa